Japan's Shionogi agreed on Oct 5 to acquire US rare-disease drugmaker IntraBio for about $2bn, gaining global rights to Aqneursa.
Regulatory approvals and timing
Closing is expected between November and December after antitrust waiting periods.
Market context
Japanese drugmakers continue to buy US assets to offset domestic price pressures.
Sources
